Is miR-34a the micromanager of cancer sternness and resistance in NSCLC?

被引：0
|
作者：
MacDonagh, L. [1 ,2 ]
Gray, S. G. [1 ,2 ]
Gallagher, M. [3 ,4 ]
French, B. [3 ,4 ]
Gasch, C. [3 ,4 ]
Finn, S. P. [2 ,5 ]
Cuffe, S. [6 ]
O'Byrne, K. [7 ]
Barr, M. P. [1 ,2 ]
机构：
[1] Trinity Coll Dublin, Trinity Translat Med Inst, Thorac Oncol Res Grp, Dublin, Ireland
[2] St James Hosp, Dublin, Ireland
[3] Coombe Womens & Infants Hosp, Canc Sternness Grp, Dept Histopathol, Dublin, Ireland
[4] Trinity Coll Dublin, Dublin, Ireland
[5] Trinity Coll Dublin, Dept Histopathol, Dublin, Ireland
[6] St James Hosp, Hope Directorate, Dublin, Ireland
[7] Queensland Univ Technol, Canc & Ageing Res Program, Brisbane, Qld, Australia
来源：
LUNG CANCER | 2018年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [1] miR-34a a micromanager of cancer stemness and resistance in NSCLC
    MacDonagh, L.
    Toland, S.
    Gray, S. G.
    Gallagher, M.
    Ffrench, B.
    Gasch, C.
    Reidy, M.
    Finn, S.
    Cuffe, S.
    O'Byrne, K.
    Barr, M. P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S23 - S23
  • [2] miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit?
    Mac Donagh, L.
    Gray, S.
    Gallagher, M.
    Ffrench, B.
    Gasch, C.
    Finn, S.
    Cuffe, S.
    O'Byrne, K.
    Barr, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1968 - S1968
  • [3] miR-34a Reverses Doxorubicin Resistance in Breast Cancer
    Ye, Guolin
    He, Suqun
    Pan, Ruilin
    Zhu, Lewei
    Zhou, Dan
    Lu, RuiLiang
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2020, 10 (12) : 1820 - 1826
  • [4] INVOLVEMENT OF MiR-34A IN RESISTANCE OF BREAST CANCER CELLS TO DOCETAXEL
    Kastl, Lena
    Schofield, Andrew C.
    EJC SUPPLEMENTS, 2010, 8 (06): : 20 - 21
  • [5] miR-34a expression in human breast cancer is associated with drug resistance
    Li, Zhi-Hua
    Weng, Xueling
    Xiong, Qiu-Yun
    Tu, Jian-Hong
    Xiao, An
    Qiu, Wei
    Gong, Yu
    Hu, Er-Wei
    Huang, Songyin
    Cao, Ya-Li
    ONCOTARGET, 2017, 8 (63) : 106270 - 106282
  • [6] Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.
    Monastirioti, Alexia
    Papadaki, Chara
    Rounis, Konstantinos
    Kalapanida, Despoina
    Makrakis, Dimitrios
    Vardakis, Nikolaos
    Mavroudis, Dimitrios
    Agelaki, Sofia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] The comprehensive landscape of miR-34a in cancer research
    Li, Sijing
    Wei, Xiaohui
    He, Jinyong
    Cao, Quanquan
    Du, Danyu
    Zhan, Xiaoman
    Zeng, Yuqi
    Yuan, Shengtao
    Sun, Li
    CANCER AND METASTASIS REVIEWS, 2021, 40 (03) : 925 - 948
  • [8] Expression and role of miR-34a in bladder cancer
    Wang, Wei
    Li, Tan
    Han, Guang
    Li, Ying
    Shi, Li-hua
    Li, Hui
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 2013, 50 (02): : 87 - 92
  • [9] The comprehensive landscape of miR-34a in cancer research
    Sijing Li
    Xiaohui Wei
    Jinyong He
    Quanquan Cao
    Danyu Du
    Xiaoman Zhan
    Yuqi Zeng
    Shengtao Yuan
    Li Sun
    Cancer and Metastasis Reviews, 2021, 40 : 925 - 948
  • [10] Alternative mechanisms of miR-34a regulation in cancer
    Slabakova, Eva
    Culig, Zoran
    Remsik, Jan
    Soucek, Karel
    CELL DEATH & DISEASE, 2017, 8 : e3100 - e3100
12345